Thompson Davis & Co’s Neurocrine Biosciences NBIX Stock Holding History

Thompson Davis & Co’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$4K	Buy	+30	New	+$3.4K	0.01%	602

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Thompson Davis & Co's NBIX Position: Q3 2018 in Review

Thompson Davis & Co opened a new position in Neurocrine Biosciences (NBIX) in Q3 2018: 30 shares worth $4K. The stake represents 0.01% of the portfolio and ranks #602 among its holdings.

345 funds tracked by Wall St. Rank hold NBIX as of Q3 2018.

Thompson Davis & Co held 30 shares of Neurocrine Biosciences worth $4K as of Q3 2018.
Neurocrine Biosciences was a new Thompson Davis & Co position in Q3 2018.
Neurocrine Biosciences made up 0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #602 holding.
345 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.